# Think.Health

> Think.Health is a VC fund backing Health Care and Biotechnology. See 36 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Fürstenfeldbruck, Germany
- Total investments: 36
- Last investment: Jan 2025
- Lead investor: 33%
- Last updated: Aug 2026
- Website: http://think-health.de/

Think.Health is a VC fund in Fürstenfeldbruck focused on Health Care and Biotechnology. Think.Health invests as a boutique risk-taker in healthcare ventures. We continuously seek innovations and disruptive business models in digital healthcare, medical technologies and health service providers,

## Contacts

5 contacts available for Think.Health. Shizune tracks 4 team members at Think.Health. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/think-health?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $1.1M–$7.6M |
| Series A | $3.6M–$28M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 13 | 36% |
| Biotechnology | 7 | 19% |
| Medical Device | 5 | 14% |
| Medical | 4 | 11% |
| Health Diagnostics | 3 | 8% |

29 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 11 | 31% |
| Series A | 7 | 19% |
| Series B | 2 | 6% |
| Series C | 2 | 6% |
| Series D | 1 | 3% |

9 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Germany | 16 | 44% |
| United States | 2 | 6% |
| France | 1 | 3% |
| Switzerland | 1 | 3% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Dr. Florian Kainzinger | Managing Partner & Founder | 2 | https://shizune.co/investors/profile/florian-kainzinger |
| Rob Hamilton | Senior Vice President Of Sales | 0 | https://shizune.co/investors/profile/rob-hamilton-7c8d |
| Dr. Michael Ruoff | Partner | 0 | https://shizune.co/investors/profile/dr-michael-ruoff |
| Nils Bottler | Venture Partner | 1 | https://shizune.co/investors/profile/nils-bottler |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Robeaute | Robeaute is a research and development agency that develops neurosurgical microrobots that can adapt to different types of medical evidence. | $28M | Series A | Jan 14, 2025 |  |
| Inflammatix | Inflammatix develops novel molecular diagnostics for acute infections and sepsis that work by 'reading' the immune system. It is a molecular diagnostics company developing rapid tests that read the immune system to resolve major clinical and public health challenges.They are initially focused on developing tests for acute bacterial andviral infections, and sepsis based on patent-pending biomarkers exclusively licensed from Stanford University. | $57M | Series E | Sep 12, 2024 |  |
| Sphingotec GmbH | SphingoTec is a biomaker company that develops and markets in vitro diagnostic solutions for novel and proprietary blood-based protein biomarkers. They also develop microtiter plates, which are a standard tool in analytical research and diagnostic testing laboratories. They develop biomakers to address diagnostically underserved critical careconditions such as acute kidney injury, sepsis, and acute heart failure. | $5.5M | Series C | Aug 08, 2024 |  |
| Myo | Myo is a communication platform for the care market.they are proud to have designed a product with Myo that brings together people in care.their team is always looking for new talents who would like to work on a product for better care. | $8.6M | Series A | Jan 31, 2024 |  |
| Selfapy | Selfapy offers a therapy support tool that helps recognize negative patterns of thought and train new behavior. Selfapy is your guided, self-help online course against depression with a personal psychologist as a companion. | $7.5M | Venture - Series Unknown | Feb 17, 2023 |  |
| Navignostics | Our mission is to identify the ideal treatment to battle each cancer patient’s disease and reduce suffering throughout their journey.At Navignostics we characterize tumors using spatial single-cell proteomics. We use our unique capabilities to identify a cancer treatment that will optimally fight each patient’s tumor. We also accelerate cancerdrug development by providing key insights into drug mechanisms and tumor features for companion diagnostic development.Our highly robust and reliable technology and our leading data analytics position us ideally to enable precision cancer diagnostics for patients and to provide services to pharma and biotech partners.This way we help people suffering from cancer by making more drugs available and by finding the right one for every patient. | $7.6M | Seed | Nov 09, 2022 |  |
| Vara | Vara develops a breast cancer screening platform powered by AI for radiologists, allowing them to focus on finding cancer early. While we provide. Vara also provides remote mammography reading services to those that lack the radiologists. Vara's mission is to make affordable diagnostics available all over the world by designing machinelearning-powered workflows that users love to work with. | $4.5M | Series A | Oct 25, 2022 |  |
| anvajo | Originally started at TU Dresden, anvajo can now look back on several years of innovative research and successful product development with uninterrupted growth. As part of the business expansion and ongoing team building, anvajo moved into its new headquarters in Dresden in January 2020. On 1300 m² practically all areas, including development,production and support functions are united under one roof. | $17.3M | Series A | Oct 19, 2022 |  |
| Inflammatix | Inflammatix develops novel molecular diagnostics for acute infections and sepsis that work by 'reading' the immune system. It is a molecular diagnostics company developing rapid tests that read the immune system to resolve major clinical and public health challenges.They are initially focused on developing tests for acute bacterial andviral infections, and sepsis based on patent-pending biomarkers exclusively licensed from Stanford University. | $102M | Series D | Mar 16, 2021 |  |
| Myo | Myo is a communication platform for the care market.they are proud to have designed a product with Myo that brings together people in care.their team is always looking for new talents who would like to work on a product for better care. |  | Series A | Oct 25, 2020 |  |

10 of 36 investments shown.

## Co-investors
- [Mountain Partners](https://shizune.co/investors/profile/mountain-partners) — VC Fund, 4 deals together
- [Northpond Ventures](https://shizune.co/investors/profile/northpond-ventures) — VC Fund, 4 deals together
- [Atlantic](https://shizune.co/investors/profile/atlantic-labs) — VC Fund, 3 deals together
- [Axel Springer Plug and Play Accelerator](https://shizune.co/investors/profile/axel-springer-plug-and-play-accelerator) — VC Fund, 3 deals together
- [BONVENTURE](https://shizune.co/investors/profile/bonventure) — VC Fund, 3 deals together
- [D1 Capital Partners](https://shizune.co/investors/profile/d1-capital-partners) — VC Fund, 3 deals together

## Similar investors

### Similar industry
- [Casa Verde Capital](https://shizune.co/investors/profile/casa-verde-capital) — VC Fund
- [Poseidon Asset Management](https://shizune.co/investors/profile/poseidon-assetmanagement) — VC Fund
- [Phyto Partners](https://shizune.co/investors/profile/phyto-partners) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [HTGF (High-Tech Gruenderfonds)](https://shizune.co/investors/profile/high-tech-gr%C3%BCnderfonds) — VC Fund
- [HV Capital](https://shizune.co/investors/profile/holtzbrinck-ventures) — VC Fund
- [IBB Ventures](https://shizune.co/investors/profile/ibb) — VC Fund

## Featured in investor lists
- [Health Care Investors in Germany](https://shizune.co/investors/health-care-investors-germany)
- [Health Care VC Funds in Germany](https://shizune.co/investors/health-care-vc-funds-germany)
- [Health Care Investors in Europe](https://shizune.co/investors/health-care-investors-europe)
- [Health Care VC Funds in Europe](https://shizune.co/investors/health-care-vc-funds-europe)
- [Hospitality Investors in Germany](https://shizune.co/investors/hospitality-investors-germany)
- [Hospitality VC Funds in Germany](https://shizune.co/investors/hospitality-vc-funds-germany)

## FAQ

### What does Think.Health invest in?

Think.Health invests primarily in Health Care, Biotechnology and Medical Device startups, most often at Seed and Series A stage. Most of the 36 investments tracked by Shizune back companies in Germany. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Think.Health's check size?

Think.Health typically joins rounds of $1.1M–$7.6M at Seed and $3.6M–$28M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Think.Health participates in.

### How do I contact Think.Health?

Public channels for Think.Health include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Think.Health?

The team at Think.Health includes Dr. Florian Kainzinger (Managing Partner & Founder), Rob Hamilton (Senior Vice President Of Sales) and Dr. Michael Ruoff (Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co